These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 31667945)

  • 1. Hepatitis B virus pregenomic RNA status can reveal the long-term prognoses of chronic hepatitis B patients treated with nucleos(t)ide analogues.
    Luo H; Tan N; Kang Q; Pan J; Chen H; Xi H; Yu M; Xu X
    J Viral Hepat; 2020 Mar; 27(3):323-328. PubMed ID: 31667945
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factors and virological significance of hepatitis B virus pregenomic RNA status after 5 years of antiviral therapy.
    Pan J; Xu J; Luo H; Tan N; Kang Q; Chen H; Cheng R; Han Y; Yang Y; Xu X
    Int J Infect Dis; 2021 Apr; 105():418-423. PubMed ID: 33676002
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Serum hepatitis B virus pregenomic RNA profiles in patients with chronic hepatitis B on long-term antiviral therapy].
    Pan JL; Luo H; Zhang XX; Han YF; Chen HY; Zeng Z; Xu XY
    Zhonghua Gan Zang Bing Za Zhi; 2024 Jan; 32(1):16-21. PubMed ID: 38320786
    [No Abstract]   [Full Text] [Related]  

  • 4. Serum hepatitis B virus RNA detectability, composition and clinical significance in patients with ab initio hepatitis B e antigen negative chronic hepatitis B.
    Laras A; Papatheodoridi M; Panopoulou E; Papatheodoridis GV; Hadziyannis SJ; Hadziyannis E
    Virol J; 2022 Jan; 19(1):22. PubMed ID: 35093105
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factors associated with the biphasic kinetics of serum HBV RNA in patients with HBeAg-positive chronic hepatitis B treated with nucleos(t)ide analogues.
    Liu S; Liu Z; Li W; Zhou B; Liang X; Fan R; Deng R; Hou J; Sun J
    Aliment Pharmacol Ther; 2020 Aug; 52(4):692-700. PubMed ID: 32613672
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pregenomic HBV RNA and Hepatitis B Core-Related Antigen Predict Outcomes in Hepatitis B e Antigen-Negative Chronic Hepatitis B Patients Suppressed on Nucleos(T)ide Analogue Therapy.
    Carey I; Gersch J; Wang B; Moigboi C; Kuhns M; Cloherty G; Dusheiko G; Agarwal K
    Hepatology; 2020 Jul; 72(1):42-57. PubMed ID: 31701544
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis B virus DNA: a randomised, controlled, open-label trial.
    Bourlière M; Rabiega P; Ganne-Carrie N; Serfaty L; Marcellin P; Barthe Y; Thabut D; Guyader D; Hezode C; Picon M; Causse X; Leroy V; Bronowicki JP; Carrieri P; Riachi G; Rosa I; Attali P; Molina JM; Bacq Y; Tran A; Grangé JD; Zoulim F; Fontaine H; Alric L; Bertucci I; Bouvier-Alias M; Carrat F;
    Lancet Gastroenterol Hepatol; 2017 Mar; 2(3):177-188. PubMed ID: 28404133
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Predictive Value of Baseline Serum Marker Levels for the Effect of Interferon Therapy in Patients With Chronic Hepatitis B].
    Yan Y; Davgadorj C; Lyu C; Lu Z; Yu P
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2024 Mar; 55(2):383-390. PubMed ID: 38645851
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The relationship between serum HBV pgRNA and antigen status in patients with chronic hepatitis B after long-term nucleotide analogues treatment].
    Rao X; Shi HH; Wu ZP; Li XP; Liu XY; Zhang LL
    Zhonghua Gan Zang Bing Za Zhi; 2021 Aug; 29(8):766-770. PubMed ID: 34517458
    [No Abstract]   [Full Text] [Related]  

  • 10. Long-term outcomes after nucleos(t)ide analogues discontinuation in chronic hepatitis B patients with HBeAg-negative.
    He D; Guo S; Chen W; Chen X; Yan G; Wang J; Li M; Zhu P; Huang H; Wang Y
    BMC Infect Dis; 2013 Oct; 13():458. PubMed ID: 24090287
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatitis B virus-specific T cell responses after stopping nucleos(t)ide analogue therapy in HBeAg-negative chronic hepatitis B.
    Rinker F; Zimmer CL; Höner Zu Siederdissen C; Manns MP; Kraft ARM; Wedemeyer H; Björkström NK; Cornberg M
    J Hepatol; 2018 Sep; 69(3):584-593. PubMed ID: 29758333
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatitis B Virus Serum DNA andRNA Levels in Nucleos(t)ide Analog-Treated or Untreated Patients During Chronic and Acute Infection.
    Butler EK; Gersch J; McNamara A; Luk KC; Holzmayer V; de Medina M; Schiff E; Kuhns M; Cloherty GA
    Hepatology; 2018 Dec; 68(6):2106-2117. PubMed ID: 29734472
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Limited sustained response after stopping nucleos(t)ide analogues in patients with chronic hepatitis B: results from a randomised controlled trial (Toronto STOP study).
    Liem KS; Fung S; Wong DK; Yim C; Noureldin S; Chen J; Feld JJ; Hansen BE; Janssen HLA
    Gut; 2019 Dec; 68(12):2206-2213. PubMed ID: 31462554
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnostic Value of Detection of Pregenomic RNA in Sera of Hepatitis B Virus-Infected Patients with Different Clinical Outcomes.
    Lin N; Ye A; Lin J; Liu C; Huang J; Fu Y; Wu S; Xu S; Wang L; Ou Q
    J Clin Microbiol; 2020 Jan; 58(2):. PubMed ID: 31723011
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HBV/Pregenomic RNA Increases the Stemness and Promotes the Development of HBV-Related HCC Through Reciprocal Regulation With Insulin-Like Growth Factor 2 mRNA-Binding Protein 3.
    Ding WB; Wang MC; Yu J; Huang G; Sun DP; Liu L; Zhang JN; Yang Y; Liu H; Zhou WP; Yang F; Yuan SX
    Hepatology; 2021 Sep; 74(3):1480-1495. PubMed ID: 33825218
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HBV pgRNA profiles in Chinese HIV/HBV coinfected patients under pre- and posttreatment: a multicentre observational cohort study.
    Xu L; Li X; Lu L; Liu X; Song X; Li Y; Han Y; Zhu T; Cao W; Li T
    J Viral Hepat; 2022 Aug; 29(8):616-626. PubMed ID: 35582838
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduction of covalently closed circular DNA with long-term nucleos(t)ide analogue treatment in chronic hepatitis B.
    Lai CL; Wong D; Ip P; Kopaniszen M; Seto WK; Fung J; Huang FY; Lee B; Cullaro G; Chong CK; Wu R; Cheng C; Yuen J; Ngai V; Yuen MF
    J Hepatol; 2017 Feb; 66(2):275-281. PubMed ID: 27639844
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Distribution and factors associated with serum HBV pregenomic RNA levels in Chinese chronic hepatitis B patients.
    Wang ML; Liao J; Ye F; Tao YC; Wu DB; He M; Tang H; Chen EQ
    J Med Virol; 2021 Jun; 93(6):3688-3696. PubMed ID: 32949174
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term continuous entecavir therapy in nucleos(t)ide-naïve chronic hepatitis B patients.
    Ono A; Suzuki F; Kawamura Y; Sezaki H; Hosaka T; Akuta N; Kobayashi M; Suzuki Y; Saitou S; Arase Y; Ikeda K; Kobayashi M; Watahiki S; Mineta R; Kumada H
    J Hepatol; 2012 Sep; 57(3):508-14. PubMed ID: 22659518
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HBV pregenome RNA as a predictor of spontanous HBeAg seroconversion in HBeAg-positive chronic hepatitis B patients.
    Song G; Yang R; Jin Q; Liu J; Rao H; Feng B; Xie Y
    BMC Gastroenterol; 2023 Nov; 23(1):381. PubMed ID: 37946120
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.